News: December 2011 - Nucana, a Scottish company have announced new funding and a phase 1 trial on NUC 1031 against panctreatic cancer December 2011 - New data released by Inhibitex reveal that INX-189 at higher doses in combination with ribavirin continued to show synergistic activity against hepatitis C November 2011 - Inhibitex have just reported that INX-189, first synthesised in this School, produced a more than 10,000 reduction in viral load in patients treated with 200mg daily for 7 days, with very few side effects
December 2011 - New data released by Inhibitex reveal that INX-189 at higher doses in combination with ribavirin continued to show synergistic activity against hepatitis C
Home
Publications
People
Biography
Teaching Material
Problem Class Topics
Email: Chris McGuigan
Office: (029)20874537 Lab: (029) 20874551 Fax: (029) 20874537
